Cardiac transplantation remains the definitive therapeutic option for irreversible end-stage heart failure, requiring careful candidate selection by an interdisciplinary team and access to mechanical circulatory support.
Answers are grounded in this paper and cite their sources.
Supports transplant as definitive for end-stage HF; leaves open refinement of selection criteria with advancing MCS options.
End-stage heart failure is still associated with a decrease in quality and prognosis of life. Cardiac transplantation remains the final extraordinary therapeutic option for the treatment of truly irreversible end-stage heart failure in all age groups. The selection process of candidates and the acceptance of patients with relative contra-indications is characterized by the experience and skills of an interdisciplinary transplant team, which should have access to different mechanical circulatory support systems for short-term or long-term use: bridging to transplant as well as for recovery.
No takes yet. Share an insight, caveat, or question.
Koerner et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: